PLGA-PDO Nanofiber Membrane for Linear Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug-loaded fiber membranes exhibit exponential drug release, which is not conducive to effective absorption, leading to poor therapeutic outcomes due to low local concentrations at wound or lesion sites, and pose potential toxicity risks from uneven drug distribution.
Innovation Solution
A drug-loaded nanofiber membrane comprising a first fiber made from poly(lactic-co-glycolic acid) (PLGA) copolymer with high swelling capacity and a second fiber from poly(p-dioxanone) (PDO) with low swelling capacity, where the drug is dispersed in the PLGA fiber, allowing controlled release through electrostatic spinning, achieving a stable and porous matrix for targeted drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional drug-loaded fiber membranes are prepared by electrostatic spinning technology, then the fiber membrane can be formed with drug loading, but the drugs are released exponentially rather than linearly, leading to poor therapeutic effect
Solution Approach 1:
The patent uses a composite fiber structure consisting of PLGA fibers (drug-loaded, high swelling capacity) and PDO fibers (low swelling capacity, structural support). This composite approach enables controlled linear drug release by combining the drug-release properties of PLGA with the structural stability of PDO, resolving the contradiction between duration of action and therapeutic reliability.
Solution Approach 2:
The patent applies local quality by creating fibers with different swelling capacities within the same membrane structure. PLGA fibers provide localized drug release functionality while PDO fibers provide localized structural support. This differentiation allows the membrane to achieve both prolonged drug release and reliable therapeutic effect simultaneously.
2Quantity of substance
If oral or intravenous administration is used, then drugs can be delivered systemically, but the drug utilization rate is low and potential toxic effects occur
Solution Approach 1:
The patent extracts the drug delivery function from systemic administration and localizes it to the wound site through a topical fiber membrane. This extraction of the therapeutic action from the bloodstream to the local application site increases drug utilization rate and eliminates systemic toxic effects by keeping the drug confined to the treatment area.
3Quantity of substance
If drugs are loaded on the surface of fiber membrane or blended with polymer, then drug loading is achieved, but the drugs are released exponentially not linearly
Solution Approach 1:
The patent employs composite materials with PLGA and PDO fibers in specific ratios to transform the exponential release pattern into a linear one. The PLGA fibers provide sustained drug release through controlled degradation, while PDO fibers maintain structural integrity, together achieving linear release over an extended duration.
Solution Approach 2:
The patent changes the physical and chemical parameters of the fiber membrane by selecting specific polymer compositions, molecular weights, and fiber diameter ranges. These parameter changes control the degradation rate and swelling behavior, enabling linear drug release instead of exponential release while maintaining effective drug loading.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanofiber membrane provides a controlled drug release cycle from 1 day to 26 days, maintaining effective drug concentrations at the site of application without sudden toxicity, and is degradable and non-toxic, suitable for postoperative use without secondary surgery.
Implementation Method 1
the first fiber has a relatively high swelling capacity, so that the first fiber swells in vivo and bonds together, thereby blocking the release of drug from the channels in the first fiber
Implementation Method 2
Conventional drug-loaded fiber membranes are prepared by electrostatic spinning technology
Data Source
AI summary
A drug-loaded nanofiber membrane includes a first fiber, a second fiber, and a drug. The drug is dispersed into the first fiber. The first fiber includes poly(lactic-co-glycolic acid) copolymer (PLGA copolymer), and the second fiber includes poly(p-dioxanone) (PDO).